1	4	_	_	_	_	_	_	_	_
2	.	_	_	_	_	_	_	_	_


1	Discussion	_	_	_	_	_	_	_	_


1	Here	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	we	_	_	_	_	_	_	_	_
4	show	_	_	_	_	_	_	_	_
5	that	_	_	_	_	_	_	_	_
6	the	_	_	_	_	_	_	_	_
7	primary	_	_	_	_	_	_	_	_
8	infection	_	_	_	_	_	_	_	_
9	of	_	_	_	_	_	_	_	_
10	mice	_	_	_	_	_	_	_	_
11	with	_	_	_	_	_	_	_	_
12	IDV	_	_	_	_	_	_	_	_
13	does	_	_	_	_	_	_	_	_
14	not	_	_	_	_	_	_	_	_
15	result	_	_	_	_	_	_	_	_
16	in	_	_	_	_	_	_	_	_
17	disease	_	_	_	_	_	_	_	_
18	,	_	_	_	_	_	_	_	_
19	as	_	_	_	_	_	_	_	_
20	mice	_	_	_	_	_	_	_	_
21	demonstrated	_	_	_	_	_	_	_	_
22	none	_	_	_	_	_	_	_	_
23	of	_	_	_	_	_	_	_	_
24	the	_	_	_	_	_	_	_	_
25	clinical	_	_	_	_	_	_	_	_
26	symptoms	_	_	_	_	_	_	_	_
27	associated	_	_	_	_	_	_	_	_
28	with	_	_	_	_	_	_	_	_
29	the	_	_	_	_	_	_	_	_
30	typical	_	_	_	_	_	_	_	_
31	progression	_	_	_	_	_	_	_	_
32	of	_	_	_	_	_	_	_	_
33	IAV	_	_	_	_	_	_	_	_
34	infection	_	_	_	_	_	_	_	_
35	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	addition	_	_	_	_	_	_	_	_
3	,	_	_	_	_	_	_	_	_
4	infection	_	_	_	_	_	_	_	_
5	with	_	_	_	_	_	_	_	_
6	IDV	_	_	_	_	_	_	_	_
7	did	_	_	_	_	_	_	_	_
8	not	_	_	_	_	_	_	_	_
9	inhibit	_	_	_	_	_	_	_	_
10	bacterial	_	_	_	_	_	_	_	_
11	clearance	_	_	_	_	_	_	_	_
12	after	_	_	_	_	_	_	_	_
13	secondary	_	_	_	_	_	_	_	_
14	challenge	_	_	_	_	_	_	_	_
15	with	_	_	_	_	_	_	_	_
16	S.	_	_	_	_	_	_	_	_
17	aureus	_	_	_	_	_	_	_	_
18	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	fact	_	_	_	_	_	_	_	_
3	,	_	_	_	_	_	_	_	_
4	we	_	_	_	_	_	_	_	_
5	found	_	_	_	_	_	_	_	_
6	decreased	_	_	_	_	_	_	_	_
7	morbidity	_	_	_	_	_	_	_	_
8	and	_	_	_	_	_	_	_	_
9	increased	_	_	_	_	_	_	_	_
10	survival	_	_	_	_	_	_	_	_
11	of	_	_	_	_	_	_	_	_
12	IDV-infected	_	_	_	_	_	_	_	_
13	mice	_	_	_	_	_	_	_	_
14	in	_	_	_	_	_	_	_	_
15	response	_	_	_	_	_	_	_	_
16	to	_	_	_	_	_	_	_	_
17	bacterial	_	_	_	_	_	_	_	_
18	challenge	_	_	_	_	_	_	_	_
19	when	_	_	_	_	_	_	_	_
20	compared	_	_	_	_	_	_	_	_
21	to	_	_	_	_	_	_	_	_
22	mice	_	_	_	_	_	_	_	_
23	that	_	_	_	_	_	_	_	_
24	were	_	_	_	_	_	_	_	_
25	challenged	_	_	_	_	_	_	_	_
26	with	_	_	_	_	_	_	_	_
27	bacteria	_	_	_	_	_	_	_	_
28	alone	_	_	_	_	_	_	_	_
29	.	_	_	_	_	_	_	_	_


1	Our	_	_	_	_	_	_	_	_
2	findings	_	_	_	_	_	_	_	_
3	demonstrate	_	_	_	_	_	_	_	_
4	that	_	_	_	_	_	_	_	_
5	mice	_	_	_	_	_	_	_	_
6	are	_	_	_	_	_	_	_	_
7	not	_	_	_	_	_	_	_	_
8	susceptible	_	_	_	_	_	_	_	_
9	to	_	_	_	_	_	_	_	_
10	secondary	_	_	_	_	_	_	_	_
11	bacterial	_	_	_	_	_	_	_	_
12	infection	_	_	_	_	_	_	_	_
13	post-IDV	_	_	_	_	_	_	_	_
14	infection	_	_	_	_	_	_	_	_
15	and	_	_	_	_	_	_	_	_
16	suggest	_	_	_	_	_	_	_	_
17	that	_	_	_	_	_	_	_	_
18	IDV-mediated	_	_	_	_	_	_	_	_
19	anti-viral	_	_	_	_	_	_	_	_
20	host	_	_	_	_	_	_	_	_
21	responses	_	_	_	_	_	_	_	_
22	may	_	_	_	_	_	_	_	_
23	help	_	_	_	_	_	_	_	_
24	to	_	_	_	_	_	_	_	_
25	clear	_	_	_	_	_	_	_	_
26	the	_	_	_	_	_	_	_	_
27	bacteria	_	_	_	_	_	_	_	_
28	by	_	_	_	_	_	_	_	_
29	priming	_	_	_	_	_	_	_	_
30	a	_	_	_	_	_	_	_	_
31	protective	_	_	_	_	_	_	_	_
32	inflammatory	_	_	_	_	_	_	_	_
33	response	_	_	_	_	_	_	_	_
34	.	_	_	_	_	_	_	_	_


1	We	_	_	_	_	_	_	_	_
2	will	_	_	_	_	_	_	_	_
3	discuss	_	_	_	_	_	_	_	_
4	these	_	_	_	_	_	_	_	_
5	results	_	_	_	_	_	_	_	_
6	in	_	_	_	_	_	_	_	_
7	the	_	_	_	_	_	_	_	_
8	context	_	_	_	_	_	_	_	_
9	of	_	_	_	_	_	_	_	_
10	IDV	_	_	_	_	_	_	_	_
11	pathogenesis	_	_	_	_	_	_	_	_
12	and	_	_	_	_	_	_	_	_
13	the	_	_	_	_	_	_	_	_
14	regulation	_	_	_	_	_	_	_	_
15	of	_	_	_	_	_	_	_	_
16	secondary	_	_	_	_	_	_	_	_
17	bacterial	_	_	_	_	_	_	_	_
18	infections	_	_	_	_	_	_	_	_
19	as	_	_	_	_	_	_	_	_
20	they	_	_	_	_	_	_	_	_
21	compare	_	_	_	_	_	_	_	_
22	with	_	_	_	_	_	_	_	_
23	our	_	_	_	_	_	_	_	_
24	previous	_	_	_	_	_	_	_	_
25	findings	_	_	_	_	_	_	_	_
26	with	_	_	_	_	_	_	_	_
27	IAV	_	_	_	_	_	_	_	_
28	.	_	_	_	_	_	_	_	_


1	Our	_	_	_	_	_	_	_	_
2	results	_	_	_	_	_	_	_	_
3	demonstrate	_	_	_	_	_	_	_	_
4	that	_	_	_	_	_	_	_	_
5	infection	_	_	_	_	_	_	_	_
6	of	_	_	_	_	_	_	_	_
7	mice	_	_	_	_	_	_	_	_
8	with	_	_	_	_	_	_	_	_
9	OK11	_	_	_	_	_	_	_	_
10	IDV	_	_	_	_	_	_	_	_
11	does	_	_	_	_	_	_	_	_
12	not	_	_	_	_	_	_	_	_
13	cause	_	_	_	_	_	_	_	_
14	mice	_	_	_	_	_	_	_	_
15	to	_	_	_	_	_	_	_	_
16	exhibit	_	_	_	_	_	_	_	_
17	the	_	_	_	_	_	_	_	_
18	clinical	_	_	_	_	_	_	_	_
19	symptoms	_	_	_	_	_	_	_	_
20	that	_	_	_	_	_	_	_	_
21	are	_	_	_	_	_	_	_	_
22	normally	_	_	_	_	_	_	_	_
23	associated	_	_	_	_	_	_	_	_
24	with	_	_	_	_	_	_	_	_
25	influenza	_	_	_	_	_	_	_	_
26	disease	_	_	_	_	_	_	_	_
27	progression	_	_	_	_	_	_	_	_
28	.	_	_	_	_	_	_	_	_


1	Although	_	_	_	_	_	_	_	_
2	we	_	_	_	_	_	_	_	_
3	did	_	_	_	_	_	_	_	_
4	observe	_	_	_	_	_	_	_	_
5	the	_	_	_	_	_	_	_	_
6	recruitment	_	_	_	_	_	_	_	_
7	of	_	_	_	_	_	_	_	_
8	lymphocytes	_	_	_	_	_	_	_	_
9	and	_	_	_	_	_	_	_	_
10	neutrophils	_	_	_	_	_	_	_	_
11	to	_	_	_	_	_	_	_	_
12	the	_	_	_	_	_	_	_	_
13	lung	_	_	_	_	_	_	_	_
14	during	_	_	_	_	_	_	_	_
15	OK11	_	_	_	_	_	_	_	_
16	infection	_	_	_	_	_	_	_	_
17	,	_	_	_	_	_	_	_	_
18	we	_	_	_	_	_	_	_	_
19	did	_	_	_	_	_	_	_	_
20	not	_	_	_	_	_	_	_	_
21	observe	_	_	_	_	_	_	_	_
22	a	_	_	_	_	_	_	_	_
23	decrease	_	_	_	_	_	_	_	_
24	in	_	_	_	_	_	_	_	_
25	body	_	_	_	_	_	_	_	_
26	weight	_	_	_	_	_	_	_	_
27	.	_	_	_	_	_	_	_	_


1	Usually	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	the	_	_	_	_	_	_	_	_
4	recruitment	_	_	_	_	_	_	_	_
5	of	_	_	_	_	_	_	_	_
6	inflammatory	_	_	_	_	_	_	_	_
7	cells	_	_	_	_	_	_	_	_
8	results	_	_	_	_	_	_	_	_
9	in	_	_	_	_	_	_	_	_
10	increased	_	_	_	_	_	_	_	_
11	signs	_	_	_	_	_	_	_	_
12	of	_	_	_	_	_	_	_	_
13	morbidity	_	_	_	_	_	_	_	_
14	,	_	_	_	_	_	_	_	_
15	as	_	_	_	_	_	_	_	_
16	we	_	_	_	_	_	_	_	_
17	have	_	_	_	_	_	_	_	_
18	previously	_	_	_	_	_	_	_	_
19	found	_	_	_	_	_	_	_	_
20	with	_	_	_	_	_	_	_	_
21	other	_	_	_	_	_	_	_	_
22	IAV	_	_	_	_	_	_	_	_
23	subtypes	_	_	_	_	_	_	_	_
24	that	_	_	_	_	_	_	_	_
25	induce	_	_	_	_	_	_	_	_
26	cellular	_	_	_	_	_	_	_	_
27	recruitment	_	_	_	_	_	_	_	_
28	.	_	_	_	_	_	_	_	_


1	Additionally	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	we	_	_	_	_	_	_	_	_
4	did	_	_	_	_	_	_	_	_
5	not	_	_	_	_	_	_	_	_
6	see	_	_	_	_	_	_	_	_
7	a	_	_	_	_	_	_	_	_
8	decrease	_	_	_	_	_	_	_	_
9	in	_	_	_	_	_	_	_	_
10	macrophage	_	_	_	_	_	_	_	_
11	levels	_	_	_	_	_	_	_	_
12	in	_	_	_	_	_	_	_	_
13	mice	_	_	_	_	_	_	_	_
14	that	_	_	_	_	_	_	_	_
15	were	_	_	_	_	_	_	_	_
16	infected	_	_	_	_	_	_	_	_
17	with	_	_	_	_	_	_	_	_
18	IDV	_	_	_	_	_	_	_	_
19	,	_	_	_	_	_	_	_	_
20	which	_	_	_	_	_	_	_	_
21	is	_	_	_	_	_	_	_	_
22	a	_	_	_	_	_	_	_	_
23	common	_	_	_	_	_	_	_	_
24	observation	_	_	_	_	_	_	_	_
25	following	_	_	_	_	_	_	_	_
26	IAV	_	_	_	_	_	_	_	_
27	infection	_	_	_	_	_	_	_	_
28	in	_	_	_	_	_	_	_	_
29	C57BL/6	_	_	_	_	_	_	_	_
30	mice	_	_	_	_	_	_	_	_
31	.	_	_	_	_	_	_	_	_


1	These	_	_	_	_	_	_	_	_
2	results	_	_	_	_	_	_	_	_
3	indicate	_	_	_	_	_	_	_	_
4	that	_	_	_	_	_	_	_	_
5	the	_	_	_	_	_	_	_	_
6	inflammatory	_	_	_	_	_	_	_	_
7	environment	_	_	_	_	_	_	_	_
8	during	_	_	_	_	_	_	_	_
9	IDV	_	_	_	_	_	_	_	_
10	infection	_	_	_	_	_	_	_	_
11	is	_	_	_	_	_	_	_	_
12	subdued	_	_	_	_	_	_	_	_
13	when	_	_	_	_	_	_	_	_
14	compared	_	_	_	_	_	_	_	_
15	to	_	_	_	_	_	_	_	_
16	other	_	_	_	_	_	_	_	_
17	influenza	_	_	_	_	_	_	_	_
18	virus	_	_	_	_	_	_	_	_
19	infections	_	_	_	_	_	_	_	_
20	.	_	_	_	_	_	_	_	_


1	Specifically	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	the	_	_	_	_	_	_	_	_
4	high	_	_	_	_	_	_	_	_
5	level	_	_	_	_	_	_	_	_
6	of	_	_	_	_	_	_	_	_
7	macrophages	_	_	_	_	_	_	_	_
8	that	_	_	_	_	_	_	_	_
9	are	_	_	_	_	_	_	_	_
10	still	_	_	_	_	_	_	_	_
11	present	_	_	_	_	_	_	_	_
12	at	_	_	_	_	_	_	_	_
13	day	_	_	_	_	_	_	_	_
14	7	_	_	_	_	_	_	_	_
15	post-OK11	_	_	_	_	_	_	_	_
16	may	_	_	_	_	_	_	_	_
17	aid	_	_	_	_	_	_	_	_
18	in	_	_	_	_	_	_	_	_
19	preventing	_	_	_	_	_	_	_	_
20	the	_	_	_	_	_	_	_	_
21	clinical	_	_	_	_	_	_	_	_
22	symptoms	_	_	_	_	_	_	_	_
23	that	_	_	_	_	_	_	_	_
24	were	_	_	_	_	_	_	_	_
25	observed	_	_	_	_	_	_	_	_
26	after	_	_	_	_	_	_	_	_
27	IAV	_	_	_	_	_	_	_	_
28	infection	_	_	_	_	_	_	_	_
29	.	_	_	_	_	_	_	_	_


1	Similar	_	_	_	_	_	_	_	_
2	to	_	_	_	_	_	_	_	_
3	other	_	_	_	_	_	_	_	_
4	groups	_	_	_	_	_	_	_	_
5	,	_	_	_	_	_	_	_	_
6	we	_	_	_	_	_	_	_	_
7	have	_	_	_	_	_	_	_	_
8	previously	_	_	_	_	_	_	_	_
9	investigated	_	_	_	_	_	_	_	_
10	infection	_	_	_	_	_	_	_	_
11	by	_	_	_	_	_	_	_	_
12	the	_	_	_	_	_	_	_	_
13	PR8	_	_	_	_	_	_	_	_
14	strain	_	_	_	_	_	_	_	_
15	of	_	_	_	_	_	_	_	_
16	IAV	_	_	_	_	_	_	_	_
17	in	_	_	_	_	_	_	_	_
18	mice	_	_	_	_	_	_	_	_
19	and	_	_	_	_	_	_	_	_
20	demonstrated	_	_	_	_	_	_	_	_
21	that	_	_	_	_	_	_	_	_
22	primary	_	_	_	_	_	_	_	_
23	PR8	_	_	_	_	_	_	_	_
24	infection	_	_	_	_	_	_	_	_
25	can	_	_	_	_	_	_	_	_
26	increase	_	_	_	_	_	_	_	_
27	morbidity	_	_	_	_	_	_	_	_
28	and	_	_	_	_	_	_	_	_
29	mortality	_	_	_	_	_	_	_	_
30	of	_	_	_	_	_	_	_	_
31	secondary	_	_	_	_	_	_	_	_
32	bacterial	_	_	_	_	_	_	_	_
33	infection	_	_	_	_	_	_	_	_
34	as	_	_	_	_	_	_	_	_
35	compared	_	_	_	_	_	_	_	_
36	to	_	_	_	_	_	_	_	_
37	infection	_	_	_	_	_	_	_	_
38	of	_	_	_	_	_	_	_	_
39	mice	_	_	_	_	_	_	_	_
40	with	_	_	_	_	_	_	_	_
41	bacteria	_	_	_	_	_	_	_	_
42	alone	_	_	_	_	_	_	_	_
43	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	this	_	_	_	_	_	_	_	_
3	study	_	_	_	_	_	_	_	_
4	,	_	_	_	_	_	_	_	_
5	we	_	_	_	_	_	_	_	_
6	demonstrate	_	_	_	_	_	_	_	_
7	that	_	_	_	_	_	_	_	_
8	there	_	_	_	_	_	_	_	_
9	is	_	_	_	_	_	_	_	_
10	a	_	_	_	_	_	_	_	_
11	protective	_	_	_	_	_	_	_	_
12	effect	_	_	_	_	_	_	_	_
13	of	_	_	_	_	_	_	_	_
14	primary	_	_	_	_	_	_	_	_
15	IDV	_	_	_	_	_	_	_	_
16	infection	_	_	_	_	_	_	_	_
17	during	_	_	_	_	_	_	_	_
18	secondary	_	_	_	_	_	_	_	_
19	S.	_	_	_	_	_	_	_	_
20	aureus	_	_	_	_	_	_	_	_
21	infection	_	_	_	_	_	_	_	_
22	that	_	_	_	_	_	_	_	_
23	is	_	_	_	_	_	_	_	_
24	not	_	_	_	_	_	_	_	_
25	observed	_	_	_	_	_	_	_	_
26	in	_	_	_	_	_	_	_	_
27	mice	_	_	_	_	_	_	_	_
28	infected	_	_	_	_	_	_	_	_
29	with	_	_	_	_	_	_	_	_
30	bacteria	_	_	_	_	_	_	_	_
31	alone	_	_	_	_	_	_	_	_
32	.	_	_	_	_	_	_	_	_


1	Specifically	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	OK11-infected	_	_	_	_	_	_	_	_
4	mice	_	_	_	_	_	_	_	_
5	challenged	_	_	_	_	_	_	_	_
6	with	_	_	_	_	_	_	_	_
7	S.	_	_	_	_	_	_	_	_
8	aureus	_	_	_	_	_	_	_	_
9	were	_	_	_	_	_	_	_	_
10	less	_	_	_	_	_	_	_	_
11	susceptible	_	_	_	_	_	_	_	_
12	to	_	_	_	_	_	_	_	_
13	clinical	_	_	_	_	_	_	_	_
14	signs	_	_	_	_	_	_	_	_
15	of	_	_	_	_	_	_	_	_
16	disease	_	_	_	_	_	_	_	_
17	(	_	_	_	_	_	_	_	_
18	weight	_	_	_	_	_	_	_	_
19	loss	_	_	_	_	_	_	_	_
20	)	_	_	_	_	_	_	_	_
21	and	_	_	_	_	_	_	_	_
22	mortality	_	_	_	_	_	_	_	_
23	when	_	_	_	_	_	_	_	_
24	compared	_	_	_	_	_	_	_	_
25	to	_	_	_	_	_	_	_	_
26	mice	_	_	_	_	_	_	_	_
27	that	_	_	_	_	_	_	_	_
28	received	_	_	_	_	_	_	_	_
29	S.	_	_	_	_	_	_	_	_
30	aureus	_	_	_	_	_	_	_	_
31	alone	_	_	_	_	_	_	_	_
32	.	_	_	_	_	_	_	_	_


1	This	_	_	_	_	_	_	_	_
2	suggests	_	_	_	_	_	_	_	_
3	that	_	_	_	_	_	_	_	_
4	IDV	_	_	_	_	_	_	_	_
5	induces	_	_	_	_	_	_	_	_
6	host	_	_	_	_	_	_	_	_
7	anti-viral	_	_	_	_	_	_	_	_
8	mechanisms	_	_	_	_	_	_	_	_
9	that	_	_	_	_	_	_	_	_
10	are	_	_	_	_	_	_	_	_
11	protective	_	_	_	_	_	_	_	_
12	against	_	_	_	_	_	_	_	_
13	secondary	_	_	_	_	_	_	_	_
14	bacterial	_	_	_	_	_	_	_	_
15	infection	_	_	_	_	_	_	_	_
16	.	_	_	_	_	_	_	_	_


1	Interestingly	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	we	_	_	_	_	_	_	_	_
4	found	_	_	_	_	_	_	_	_
5	that	_	_	_	_	_	_	_	_
6	,	_	_	_	_	_	_	_	_
7	in	_	_	_	_	_	_	_	_
8	addition	_	_	_	_	_	_	_	_
9	to	_	_	_	_	_	_	_	_
10	OK11	_	_	_	_	_	_	_	_
11	infection	_	_	_	_	_	_	_	_
12	alone	_	_	_	_	_	_	_	_
13	,	_	_	_	_	_	_	_	_
14	secondary	_	_	_	_	_	_	_	_
15	bacterial	_	_	_	_	_	_	_	_
16	infection	_	_	_	_	_	_	_	_
17	of	_	_	_	_	_	_	_	_
18	OK11-infected	_	_	_	_	_	_	_	_
19	mice	_	_	_	_	_	_	_	_
20	also	_	_	_	_	_	_	_	_
21	does	_	_	_	_	_	_	_	_
22	not	_	_	_	_	_	_	_	_
23	decrease	_	_	_	_	_	_	_	_
24	the	_	_	_	_	_	_	_	_
25	level	_	_	_	_	_	_	_	_
26	of	_	_	_	_	_	_	_	_
27	macrophages	_	_	_	_	_	_	_	_
28	.	_	_	_	_	_	_	_	_


1	This	_	_	_	_	_	_	_	_
2	suggests	_	_	_	_	_	_	_	_
3	that	_	_	_	_	_	_	_	_
4	macrophages	_	_	_	_	_	_	_	_
5	may	_	_	_	_	_	_	_	_
6	be	_	_	_	_	_	_	_	_
7	involved	_	_	_	_	_	_	_	_
8	in	_	_	_	_	_	_	_	_
9	mediating	_	_	_	_	_	_	_	_
10	protection	_	_	_	_	_	_	_	_
11	from	_	_	_	_	_	_	_	_
12	secondary	_	_	_	_	_	_	_	_
13	bacterial	_	_	_	_	_	_	_	_
14	challenge	_	_	_	_	_	_	_	_
15	.	_	_	_	_	_	_	_	_


1	Our	_	_	_	_	_	_	_	_
2	previous	_	_	_	_	_	_	_	_
3	work	_	_	_	_	_	_	_	_
4	with	_	_	_	_	_	_	_	_
5	PR8-infected	_	_	_	_	_	_	_	_
6	C57BL/6	_	_	_	_	_	_	_	_
7	mice	_	_	_	_	_	_	_	_
8	showed	_	_	_	_	_	_	_	_
9	that	_	_	_	_	_	_	_	_
10	protective	_	_	_	_	_	_	_	_
11	alveolar	_	_	_	_	_	_	_	_
12	macrophages	_	_	_	_	_	_	_	_
13	are	_	_	_	_	_	_	_	_
14	depleted	_	_	_	_	_	_	_	_
15	over	_	_	_	_	_	_	_	_
16	the	_	_	_	_	_	_	_	_
17	course	_	_	_	_	_	_	_	_
18	of	_	_	_	_	_	_	_	_
19	IAV	_	_	_	_	_	_	_	_
20	infection	_	_	_	_	_	_	_	_
21	and	_	_	_	_	_	_	_	_
22	replaced	_	_	_	_	_	_	_	_
23	by	_	_	_	_	_	_	_	_
24	damaging	_	_	_	_	_	_	_	_
25	inflammatory	_	_	_	_	_	_	_	_
26	monocytes/neutrophils	_	_	_	_	_	_	_	_
27	that	_	_	_	_	_	_	_	_
28	contribute	_	_	_	_	_	_	_	_
29	to	_	_	_	_	_	_	_	_
30	secondary	_	_	_	_	_	_	_	_
31	bacterial	_	_	_	_	_	_	_	_
32	susceptibility	_	_	_	_	_	_	_	_
33	.	_	_	_	_	_	_	_	_


1	However	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	Califano	_	_	_	_	_	_	_	_
4	,	_	_	_	_	_	_	_	_
5	Furuya	_	_	_	_	_	_	_	_
6	,	_	_	_	_	_	_	_	_
7	and	_	_	_	_	_	_	_	_
8	Metzger	_	_	_	_	_	_	_	_
9	(	_	_	_	_	_	_	_	_
10	2013	_	_	_	_	_	_	_	_
11	)	_	_	_	_	_	_	_	_
12	demonstrated	_	_	_	_	_	_	_	_
13	that	_	_	_	_	_	_	_	_
14	macrophage	_	_	_	_	_	_	_	_
15	dysfunction	_	_	_	_	_	_	_	_
16	,	_	_	_	_	_	_	_	_
17	rather	_	_	_	_	_	_	_	_
18	than	_	_	_	_	_	_	_	_
19	depletion	_	_	_	_	_	_	_	_
20	,	_	_	_	_	_	_	_	_
21	in	_	_	_	_	_	_	_	_
22	C57BL/6	_	_	_	_	_	_	_	_
23	mice	_	_	_	_	_	_	_	_
24	that	_	_	_	_	_	_	_	_
25	were	_	_	_	_	_	_	_	_
26	infected	_	_	_	_	_	_	_	_
27	with	_	_	_	_	_	_	_	_
28	IAV	_	_	_	_	_	_	_	_
29	is	_	_	_	_	_	_	_	_
30	a	_	_	_	_	_	_	_	_
31	factor	_	_	_	_	_	_	_	_
32	that	_	_	_	_	_	_	_	_
33	contributes	_	_	_	_	_	_	_	_
34	to	_	_	_	_	_	_	_	_
35	increased	_	_	_	_	_	_	_	_
36	susceptibility	_	_	_	_	_	_	_	_
37	to	_	_	_	_	_	_	_	_
38	secondary	_	_	_	_	_	_	_	_
39	bacterial	_	_	_	_	_	_	_	_
40	infection	_	_	_	_	_	_	_	_
41	,	_	_	_	_	_	_	_	_
42	and	_	_	_	_	_	_	_	_
43	our	_	_	_	_	_	_	_	_
44	previous	_	_	_	_	_	_	_	_
45	PR8-infected	_	_	_	_	_	_	_	_
46	mouse	_	_	_	_	_	_	_	_
47	data	_	_	_	_	_	_	_	_
48	supports	_	_	_	_	_	_	_	_
49	this	_	_	_	_	_	_	_	_
50	.	_	_	_	_	_	_	_	_


1	It	_	_	_	_	_	_	_	_
2	will	_	_	_	_	_	_	_	_
3	be	_	_	_	_	_	_	_	_
4	important	_	_	_	_	_	_	_	_
5	to	_	_	_	_	_	_	_	_
6	determine	_	_	_	_	_	_	_	_
7	the	_	_	_	_	_	_	_	_
8	macrophage	_	_	_	_	_	_	_	_
9	phenotypic	_	_	_	_	_	_	_	_
10	properties	_	_	_	_	_	_	_	_
11	over	_	_	_	_	_	_	_	_
12	the	_	_	_	_	_	_	_	_
13	course	_	_	_	_	_	_	_	_
14	of	_	_	_	_	_	_	_	_
15	IDV	_	_	_	_	_	_	_	_
16	infection	_	_	_	_	_	_	_	_
17	,	_	_	_	_	_	_	_	_
18	and	_	_	_	_	_	_	_	_
19	compare	_	_	_	_	_	_	_	_
20	them	_	_	_	_	_	_	_	_
21	with	_	_	_	_	_	_	_	_
22	IAV	_	_	_	_	_	_	_	_
23	responses	_	_	_	_	_	_	_	_
24	to	_	_	_	_	_	_	_	_
25	define	_	_	_	_	_	_	_	_
26	how	_	_	_	_	_	_	_	_
27	macrophages	_	_	_	_	_	_	_	_
28	contribute	_	_	_	_	_	_	_	_
29	to	_	_	_	_	_	_	_	_
30	this	_	_	_	_	_	_	_	_
31	protection	_	_	_	_	_	_	_	_
32	from	_	_	_	_	_	_	_	_
33	secondary	_	_	_	_	_	_	_	_
34	bacterial	_	_	_	_	_	_	_	_
35	infection	_	_	_	_	_	_	_	_
36	.	_	_	_	_	_	_	_	_

